Evidence map›Paper›PMID 35077523›Full record

ArticlePloS one2022

Effects of infectious disease consultation and antimicrobial stewardship program at a Japanese cancer center: An interrupted time-series analysis.

Naoya Itoh, Nana Akazawa, Eri Kanawaku, Hiromi Murakami, Yuichi Ishibana, Daichi Kawamura, Takanori Kawabata, Keita Mori, Eiichi N Kodama, Norio Ohmagari

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Observational
  2. Observational
  3. Article
  4. Analysis of Drug-Resistant Bacteria Seasonality in Japan Using Financial Time Series Analysis Method: A Nationwide Longitudinal Study.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  5. Article
  6. The long-term impact of an antimicrobial stewardship program in febrile neutropenia: an 8 years follow up.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  7. Article
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Naoya ItohDivision of Infectious Diseases, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID 0000-0001-6269-7884
Nana AkazawaDivision of Infectious Diseases, Aichi Cancer Center Hospital, Nagoya, Japan.
Eri KanawakuDivision of Infectious Diseases, Aichi Cancer Center Hospital, Nagoya, Japan.
Hiromi MurakamiDivision of Infectious Diseases, Aichi Cancer Center Hospital, Nagoya, Japan.
Yuichi IshibanaDivision of Infectious Diseases, Aichi Cancer Center Hospital, Nagoya, Japan.
Daichi KawamuraDivision of Infectious Diseases, Aichi Cancer Center Hospital, Nagoya, Japan.
Takanori KawabataClinical Trial Coordination Office, Shizuoka Cancer Center, Shizuoka, Japan.
Keita MoriClinical Trial Coordination Office, Shizuoka Cancer Center, Shizuoka, Japan.ORCID 0000-0002-5473-1488
Eiichi N KodamaDivision of Infectious Diseases, International Research Institute of Disaster Science, Tohoku University and Tohoku Medical Megabank Organization, Sendai, Japan.
Norio OhmagariCollaborative Chairs Emerging and Reemerging Infectious Diseases, National Center for Global Health and Medicine, Graduate School of Medicine, Tohoku University, Miyagi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In cancer patients, appropriate diagnosis and management of infection are frequently challenging owing to subtle or atypical presentation. We investigated the effectiveness of infectious disease (ID) consultations and the Antimicrobial Stewardship Program (ASP) in a Japanese cancer center. This 36-month-period, single-institution, interrupted time series analysis was retrospectively conducted during April 1, 2018-March 31, 2021, to evaluate a two-phase intervention: Phase 1 (notification of antimicrobials by the infection control team) and Phase 2 (establishing an ID consultation service and implementing ASP). Among 32,202 patients hospitalized, 22,096 and 10,106 hospitalizations occurred at baseline and during intervention period, respectively. The Antimicrobial Stewardship Team (AST) provided feedback on specific broad-spectrum antimicrobials in 913 instances (347 appropriate [38%]; 566 inappropriate [62%]), and 440 ID consultations were completed, with a 75% overall acceptance rate for AST suggestions. In Phase 2, monthly carbapenem days of therapy (CAR-DOT) decreased significantly, and narrow-spectrum antibiotic usage increased significantly in both trend and level; monthly DOT of antipseudomonal agents decreased significantly in trend. The results of these analyses of antimicrobial use are consistent with the DOT-based data based on antimicrobial use density (AUD). The total number of inpatient specimens increased significantly; the trend of multidrug-resistant Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infections decreased, without changes in the incidence of other resistant organisms, all-cause in-hospital mortality, and length of stay. Actual and adjusted CAR purchase costs per patient-day decreased without significant changes in the actual and adjusted purchase cost per patient-day for all intravenous antimicrobials. Combining ID consultation and ASP reduced carbapenem use without negative patient outcomes. Their implementation could facilitate establishment of safe cancer treatment facilities in Japan and improve prognosis in cancer patients.

Indexed as

Antimicrobial StewardshipCancer Care FacilitiesHospital MortalityMethicillin-Resistant Staphylococcus aureusNeoplasmsPseudomonas aeruginosaPseudomonas InfectionsStaphylococcal InfectionsAnti-Bacterial AgentsFemaleHumansJapanMaleMiddle AgedRetrospective StudiesAnti-Bacterial Agents

Identifiers

PMID35077523
PMCPMC8789186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.